サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1317834

肺がん治療薬市場：疾患別、分子別、流通チャネル別-2023-2030年の世界予測

Lung Cancer Drugs Market by Disease, Molecule, Distribution Channel - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 190 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
肺がん治療薬市場：疾患別、分子別、流通チャネル別-2023-2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 190 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

肺がん治療薬の世界市場は、2023年に247億6,000万米ドル、CAGR 9.04%で大きく成長し、2030年には454億5,000万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の肺がん治療薬市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.肺がん治療薬の世界市場規模および予測は？

2.予測期間中、世界の肺がん治療薬市場を形成するCOVID-19の阻害要因と影響は？

3.肺がん治療薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.肺がん治療薬の世界市場における競争戦略は？

5.肺がん治療薬の世界市場における技術動向と規制の枠組みは？

6.肺がん治療薬の世界市場における主要ベンダーの市場シェアは？

7.肺がん治療薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 肺がんの症例と発生率の増加
      • 消費者による標的療法に対する需要の高まり
      • 世界中で喫煙者数が増加
      • 肺がん抑制に対する政府の好意的な支援
    • 抑制要因
      • 肺がん治療薬の副作用
    • 機会
      • 肺がん治療における継続的な調査活動
      • 新薬分野における技術の進歩
    • 課題
      • 生物学的製剤と標的療法の利用可能性と高額な肺がん治療費
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 肺がん治療薬市場：疾患別

  • 非小細胞肺がん
  • 小細胞肺がん

第7章 肺がん治療薬市場分子別

  • 生物製剤
  • 低分子

第8章 肺がん治療薬市場：流通チャネル別

  • オフライン
  • オンライン

第9章 南北アメリカの肺がん治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の肺がん治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの肺がん治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第13章 掲載企業一覧

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. LUNG CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. LUNG CANCER DRUGS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. LUNG CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2022 VS 2030 (%)
  • FIGURE 5. LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2022 VS 2030 (%)
  • FIGURE 6. LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • FIGURE 7. LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. LUNG CANCER DRUGS MARKET DYNAMICS
  • FIGURE 9. LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. LUNG CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. LUNG CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. LUNG CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. LUNG CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 5. LUNG CANCER DRUGS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. LUNG CANCER DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 8. LUNG CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. LUNG CANCER DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 11. LUNG CANCER DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. LUNG CANCER DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 38. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 39. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. CHINA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 41. CHINA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 42. CHINA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. INDIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 44. INDIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 45. INDIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. INDONESIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 47. INDONESIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 48. INDONESIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 50. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 51. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. MALAYSIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 53. MALAYSIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 54. MALAYSIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. PHILIPPINES LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 56. PHILIPPINES LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 57. PHILIPPINES LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. SINGAPORE LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 59. SINGAPORE LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 60. SINGAPORE LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 62. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 63. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. TAIWAN LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 65. TAIWAN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 66. TAIWAN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. THAILAND LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 68. THAILAND LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 69. THAILAND LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. VIETNAM LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 71. VIETNAM LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 72. VIETNAM LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. DENMARK LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 78. DENMARK LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 79. DENMARK LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. EGYPT LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 81. EGYPT LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 82. EGYPT LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. FINLAND LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 84. FINLAND LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 85. FINLAND LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 87. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 88. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 90. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 91. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. ISRAEL LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 93. ISRAEL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 94. ISRAEL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. ITALY LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 96. ITALY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 97. ITALY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. NETHERLANDS LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 99. NETHERLANDS LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 100. NETHERLANDS LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. NIGERIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 102. NIGERIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 103. NIGERIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NORWAY LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 105. NORWAY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 106. NORWAY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. POLAND LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 108. POLAND LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 109. POLAND LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. QATAR LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 111. QATAR LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 112. QATAR LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 114. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 115. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. SAUDI ARABIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 117. SAUDI ARABIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 118. SAUDI ARABIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. SOUTH AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 120. SOUTH AFRICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 123. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 124. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SWEDEN LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 126. SWEDEN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 127. SWEDEN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SWITZERLAND LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 129. SWITZERLAND LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 130. SWITZERLAND LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. TURKEY LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 132. TURKEY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 133. TURKEY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. UNITED ARAB EMIRATES LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 135. UNITED ARAB EMIRATES LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 136. UNITED ARAB EMIRATES LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. LUNG CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 141. LUNG CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 142. LUNG CANCER DRUGS MARKET LICENSE & PRICING
目次
Product Code: MRR-434CCDA05295

The Global Lung Cancer Drugs Market is forecasted to grow significantly, with a projected USD 24.76 billion in 2023 at a CAGR of 9.04% and expected to reach a staggering USD 45.45 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Lung Cancer Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Lung Cancer Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Disease, market is studied across Non-Small Cell Lung Cancer and Small Cell Lung cancer. The Non-Small Cell Lung Cancer is projected to witness significant market share during forecast period.

Based on Molecule, market is studied across Biologics and Small Molecules. The Small Molecules is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Offline and Online. The Offline is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Lung Cancer Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Lung Cancer Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Lung Cancer Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Lung Cancer Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Lung Cancer Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Lung Cancer Drugs Market?

6. What is the market share of the leading vendors in the Global Lung Cancer Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Lung Cancer Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Lung Cancer Drugs Market, by Disease, 2022 vs 2030
  • 4.3. Lung Cancer Drugs Market, by Molecule, 2022 vs 2030
  • 4.4. Lung Cancer Drugs Market, by Distribution Channel, 2022 vs 2030
  • 4.5. Lung Cancer Drugs Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising cases and incidences of lung cancer
      • 5.1.1.2. Growing demand for the targeted therapies by consumers
      • 5.1.1.3. Increase in the number of smokers across the globe
      • 5.1.1.4. Favorable government support to control lung cancer
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects of lung cancer drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research activities in the lung cancer treatments
      • 5.1.3.2. Technological advancement in the fields of novel drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of biologics & targeted therapies and high cost of lung cancer treatments
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Lung Cancer Drugs Market, by Disease

  • 6.1. Introduction
  • 6.2. Non-Small Cell Lung Cancer
  • 6.3. Small Cell Lung cancer

7. Lung Cancer Drugs Market, by Molecule

  • 7.1. Introduction
  • 7.2. Biologics
  • 7.3. Small Molecules

8. Lung Cancer Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Offline
  • 8.3. Online

9. Americas Lung Cancer Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Lung Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Lung Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing